118 results about "Leukemogenic Viruses" patented technology

The invention relates to compositions comprising mixtures of polypeptides having reverse transcriptase (RT) activity and to methods of producing, amplifying or sequencing nucleic acid molecules using these compositions or polypeptides, particularly at temperatures above about 55° C. The invention also relates to nucleic acid molecules produced by these methods, to vectors and host cells comprising these nucleic acid molecules, and use of such nucleic acid molecules to produce desired polypeptide. The invention also relates to methods for producing Avian Sarcoma-Leukosis Virus (ASLV) RT subunits, in particular, Avian Myeloblastosis Virus (AMV) RTs, to isolated nucleic acid molecules encoding ASLV RT subunits, and to ASLV RT subunits produced by these methods. The invention further relates to nucleic acid molecules encoding recombinant RT holoenzymes, particularly ASLV RTs, methods for producing these RTs and to RTs produced by these methods. The invention also relates to kits comprising the compositions, polypeptides, and ASLV RTs of the invention.

The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.

The invention provides a method for labeling antibodies by colorful fluorescent granules and a test paper strip prepared from the antibodies. Animal viruses including, but not limited to, canine distemper viruses, canine parvoviruses, canine adenoviruses, canine coronavirus, rabies viruses, feline leukemia viruses, Marek's disease viruses, Newcastle disease viruses and the like are used as targets, and the corresponding antibodies labeled by colorful fluorescent micro-spheres are prepared by the aid of chemical covalent processes and can be applied to detecting the animal viruses. The method for labeling the antibodies by the colorful fluorescent granules and the test paper strip prepared from the antibodies have the advantages that colorful detection lines with bright developed colors can appear during detection, and accordingly qualitative results can be obtained; the contents of the animal viruses in samples further can be subsequently quantitatively obtained, accordingly, test results are clear and are high in stability, and the test paper strip can be stored at the room temperature for a long time.

The invention belongs to the field of biological technical detection and particularly relates to an immune PCR reagent kit for detecting avian leukemia virus. The reagent kit comprises two antibody oligonucleotide probes, a coupled reaction solution, DNA ligase, protease, a Fast Master mixed solution and a Universal q PRC reaction solution. The immune PCR reagent kit uses a biotin-labeled avian leukemia virus preventing special antibody and a commercialized ortho-position connecting reagent, can detect avian leukemia virus antigen through immune PCR and can quickly detect the avian leukemia virus antigen in a high-throughout mode through the immune PCR without carrying out a complex nucleic acid extracting process on a sample. The immune PCR reagent kit for detecting the avian leukemia virus can be applied to clinical detection and purification of avian leukemia virus and will fill domestic and oversea correlated technique blank.

The invention belongs to the technical field of immunoassay and bio-sensing, and discloses a preparation method and an application of an avian leukemia virus antigen immunosensor which is used for quickly detecting the avian leukemia virus antigen. According to the manufacturing scheme adopted by the invention, the preparation method comprises the following steps: by taking a glassy carbon electrode as a working electrode, modifying beta-CD/MWCNTs; then, adding adamantanecarboxylic acid/capturing antibody Ab1, bovine serum albumin, avian leukemia virus antigen as well as beta-CD@Fe3O4@SiO2-Fc/Ab2 solution in sequence. The beta-CD@Fe3O4@SiO2-Fc is easy to separate due to the superparamagnetism of a ferric oxide nano material; by utilizing the supramolecular recognition characteristic of the cyclodextrin, a great deal of ferrocenecarboxylic acid Fc can be captured through the action of subjective and objective objects, the biocompatibility and the water solubility are good, so that the preparation method is beneficial for increasing the antibody detecting amount, capable of realizing relatively high sensitivity and lowering the detecting limit to 0.33pg/mL.

An application of the CP or NCP preparation in preparing the medicine for treating HIV infection or AIDS is disclosed. Said CP preparation is prepared from CP through deactivating by formaldehyde.

The invention belongs to the technical field of biomedicine and particularly relates to application of seaweed oligosaccharide in the preparation of an avian leucosis virus resistant preparation. seaweed oligosaccharide is prepared by degrading natural polysaccharides extracted from the macroalga Grateloupia filicina, Ulva lactuca, Sargassum fusiforme and other algae, has a wide source range, is simple to prepare, and has the advantages, as an antiviral preparation, such as naturalness, zero toxicity and environmental friendliness; in-vitro cell experiments prove that the seaweed oligosaccharide is capable of inhibiting the proliferation of avian leucosis virus, has significant antiviral effect, may be applied to livestock and poultry breeding as a novel antiviral preparation, and has high applicable value.

The invention discloses a multiplex detection reagent for immunosuppressive poultry pathogens of avian influenza and the like and an application of the multiplex detection reagent. The multiplex detection reagent comprises six specific probes with sequences shown in Seq ID NO.1-Seq ID NO.6 which refer to AVI virus, ND (newcastle disease) virus, serotype I Marek's disease virus, IBDV (infectious bursal disease virus), avian infectious anaemia virus and ALV-J (aivan leukosis virus subgroup J) in sequence. The reagent comprises the specific probes for six immunosuppressive poultry pathogens comprising AVI and the like and can specifically capture target sequences of the six immunosuppressive poultry pathogens, and the foundation is laid for high-throughput rapid detection of the six immunosuppressive poultry pathogens. With adoption of the reagent, a rapid and accurate detection method is provided for the six immunosuppressive poultry pathogens on the basis of a liquid chip.

The invention relates to an expression and purification of murine leukemia virus reverse transcriptase (MMLV-RT), in particular to a soluble expression and a purification method for recombinant murineleukemia virus reverse transcriptase (MMLV-RT), which belongs to the field of biochemistry. MMLV-RT genes and enterokinase restriction enzyme cutting sites are cloned in a pET28a vector through vector construction; the MMLV-RT and molecular chaperones are co-expressed at the low temperature; the expression amount of protein is improved to 15 percent; and the solubility of the protein is 10 timesthat of the protein expressed by a conventional method.

The invention relates to a method for detecting nucleic acid of a porcine reproductive and respiratory syndrome (PRRS) virus by one step, which comprises the following steps of: collecting, processing and detecting samples, wherein in the collecting step, an animal blood sample is dripped into a full type approval (FTA) card sample area; and the detecting steps comprises the: (1) designing specific primers and a probe for general type PRRS virus, and marking carboxyfluorescein (FAM) and tetramethyl rhodamine (TAMARA) fluorescent groups on the probe; and (2) preparing and optimizing a detection system and a reaction condition, wherein a reaction system comprises 25 or 50 microliters of trihydroxymethyl aminomethane-hydrogen chloride (HCl) (the pH value is between 7.8 and 9.0), 0.1 to 0.5 micro mol of upstream primer and 0.1 to 0.5 micro mol of downstream primer, 100 to 400 micro mols of deoxynucleotide mixture, 0.1 to 0.5 micro mol of probe, 100 to 300 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase, 1 to 5 U of thermostable deoxyribonucleic acid (DNA) polymerase, 4 to 8 mols of Mg<2+->, 300 to 500 nano mol of homogenized reference dyes ROX, and 1 to 15 microliters of sample which is re-suspended in trihydroxymethyl aminomethane-ethylene diamine tetraacetic acid (EDTA) buffer solution and is added before each time of reaction. In the method, the sample collection is easy and convenient, so that an FTA card containing s ribonucleic acid (RNA) sample can be posted to any one central laboratory to be detected according to a form of regular mails; and the pollution risks are reduced, and the detection sensitivity is improved.

The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors.

The invention discloses a method for staining and determining titer of an allophilic mouse leukemia virus by using a tissue half-infection method, which takes a PG4 cell as an indicator cell for detecting X-MuLV, accurately and quantitatively determines the titer of the X-MuLV by using TCID50 assay combined with a crystal violet staining method, and comprises the following steps: continuously diluting the virus; adding viruses with different dilution degrees into the cell holes; adding a cell growth solution into each pore in the pore plate, transferring into a cell incubator, and culturing for 5-7 days; terminating the culture, dyeing, and reading the number of CPE pores; and calculating virus titer. The method can overcome the defect of multiple operation procedures of a plaque determination method, and is more convenient to operate; meanwhile, in combination with cell staining, subjective errors of different persons can be effectively avoided when the cytopathic effect is observed through a microscope, and the product has the advantages of being high in sensitivity, clear in background, good in stability, high in repeatability and the like.

The invention relates to the technical field of biology and in particular relates to a kit for simultaneously detecting an avian leukosis virus antibody and a salmonella pullorum antibody. An antigencombination of the kit comprises p27 protein, gp85 protein and GroEL-delta8-1 protein. Avian leukosis virus capsid protein p27, prokaryotic expression protein of envelope protein gp85, and prokaryoticexpression protein of truncated GroEL-delta8-1 of a salmonella pullorum dominant antigen are used as a coating antigen to develop an ELISA (Enzyme-linked Immunosorbent Assay) kit capable of simultaneously detecting the avian leukosis virus antibody and the salmonella pullorum antibody. Compared with a current common kit for independently detecting avian leukosis or pullorum disease, the kit provided by the invention has the effect of simultaneously detecting the avian leukosis or the pullorum disease, and the detection and purification work of the avian leukosis and the pullorum disease can be extremely alleviated.